Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia

Jeff P. Sharman*, Steven E. Coutre, Richard R. Furman, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Eugen Tausch, Paula Cramer, Julie HuangSiddhartha Mitra, Michael Hallek, Susan M. O’Brien, Stephan Stilgenbauer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

108 Scopus citations

Fingerprint

Dive into the research topics of 'Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences